These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 16135341)

  • 1. A research agenda for economic evaluation of substance abuse services.
    French MT; Drummond M
    J Subst Abuse Treat; 2005 Sep; 29(2):125-37. PubMed ID: 16135341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines and challenges for estimating the economic costs and benefits of adolescent substance abuse treatments.
    Zavala SK; French MT; Henderson CE; Alberga L; Rowe C; Liddle HA
    J Subst Abuse Treat; 2005 Oct; 29(3):191-205. PubMed ID: 16183468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic costs of drug abuse: financial, cost of illness, and services.
    Cartwright WS
    J Subst Abuse Treat; 2008 Mar; 34(2):224-33. PubMed ID: 17596904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical review of accounting and economic methods for estimating the costs of addiction treatment.
    Cartwright WS
    J Subst Abuse Treat; 2008 Apr; 34(3):302-10. PubMed ID: 17614244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of a mixed-gender aftercare program for substance abuse: decomposing measured and unmeasured gender differences.
    Yeom HS; Shepard DS
    J Ment Health Policy Econ; 2007 Dec; 10(4):207-19. PubMed ID: 18166831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidimensional impact of treatment for substance abuse.
    Hoffmann NG; Harrison PA; Belille CA
    Adv Alcohol Subst Abuse; 1984; 3(3):83-94. PubMed ID: 6496235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A profile of the substance abuse treatment industry: organization, costs, and treatment completion.
    Woodward AM; Raskin IE; Blacklow B
    Subst Use Misuse; 2008; 43(5):647-79. PubMed ID: 18393082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and benefit-cost of peer-based workplace substance abuse prevention coupled with random testing.
    Miller TR; Zaloshnja E; Spicer RS
    Accid Anal Prev; 2007 May; 39(3):565-73. PubMed ID: 17125723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forecasting the cost of drug abuse treatment coverage in private health insurance.
    McGuire TG; Shatkin BF
    NIDA Res Monogr; 1991; 113():175-89. PubMed ID: 1762639
    [No Abstract]   [Full Text] [Related]  

  • 12. [Recent developments in the economic evaluation of health].
    Rovira J
    Med Clin (Barc); 2000; 114 Suppl 3():8-14. PubMed ID: 10994558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Health services and health economics].
    Cilingiroglu N
    Nufusbil Derg; 1988; 10():45-50. PubMed ID: 12342133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of telemedicine: review of the literature and research guidelines for benefit-cost analysis.
    Dávalos ME; French MT; Burdick AE; Simmons SC
    Telemed J E Health; 2009 Dec; 15(10):933-48. PubMed ID: 19954346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does treatment 'pay for itself'? Looking at the economic argument for addiction treatment.
    Ettner SL
    Behav Healthc; 2006 May; 26(5):32-4. PubMed ID: 16736917
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of health economics in substance abuse research. Recent advances and future opportunities. Overview.
    French MT
    Recent Dev Alcohol; 2001; 15():201-8. PubMed ID: 11449742
    [No Abstract]   [Full Text] [Related]  

  • 17. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive case management for youth with serious emotional disturbance and chemical abuse.
    Evans ME; Dollard N
    NIDA Res Monogr; 1992; 127():289-315. PubMed ID: 1436000
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost estimation when time and resources are limited: the Brief DATCAP.
    French MT; Roebuck MC; McLellan AT
    J Subst Abuse Treat; 2004 Oct; 27(3):187-93. PubMed ID: 15501371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using the DATCAP and ASI to estimate the costs and benefits of residential addiction treatment in the State of Washington.
    French MT; Salomé HJ; Carney M
    Soc Sci Med; 2002 Dec; 55(12):2267-82. PubMed ID: 12409139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.